PT2391345E - Formulações galénicas compreendendo aliscireno - Google Patents

Formulações galénicas compreendendo aliscireno Download PDF

Info

Publication number
PT2391345E
PT2391345E PT107020927T PT10702092T PT2391345E PT 2391345 E PT2391345 E PT 2391345E PT 107020927 T PT107020927 T PT 107020927T PT 10702092 T PT10702092 T PT 10702092T PT 2391345 E PT2391345 E PT 2391345E
Authority
PT
Portugal
Prior art keywords
aliskiren
galenic formulations
galenic
formulations
Prior art date
Application number
PT107020927T
Other languages
English (en)
Inventor
Sabine Desset-Brèthes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2391345(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2391345E publication Critical patent/PT2391345E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT107020927T 2009-01-28 2010-01-27 Formulações galénicas compreendendo aliscireno PT2391345E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28

Publications (1)

Publication Number Publication Date
PT2391345E true PT2391345E (pt) 2014-12-03

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107020927T PT2391345E (pt) 2009-01-28 2010-01-27 Formulações galénicas compreendendo aliscireno

Country Status (28)

Country Link
US (1) US20110287100A1 (pt)
EP (1) EP2391345B1 (pt)
JP (1) JP2012516299A (pt)
KR (1) KR20110117199A (pt)
CN (1) CN102300558A (pt)
AR (1) AR075179A1 (pt)
AU (1) AU2010209787B2 (pt)
BR (1) BRPI1007452A2 (pt)
CA (1) CA2749531A1 (pt)
CL (1) CL2011001817A1 (pt)
CO (1) CO6400184A2 (pt)
EC (1) ECSP11011289A (pt)
ES (1) ES2525648T3 (pt)
HK (1) HK1161125A1 (pt)
IL (1) IL213918A0 (pt)
MA (1) MA33060B1 (pt)
MX (1) MX2011007779A (pt)
MY (1) MY153852A (pt)
NZ (1) NZ593622A (pt)
PE (1) PE20110943A1 (pt)
PL (1) PL2391345T3 (pt)
PT (1) PT2391345E (pt)
RU (1) RU2535090C2 (pt)
SG (1) SG172226A1 (pt)
TN (1) TN2011000307A1 (pt)
TW (1) TWI468191B (pt)
WO (1) WO2010086312A1 (pt)
ZA (1) ZA201104489B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
CA3010778C (en) 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
JP7461295B2 (ja) * 2018-08-10 2024-04-03 キッセイ薬品工業株式会社 スクロオキシ水酸化鉄含有顆粒及び医薬組成物
CN113490486A (zh) 2019-02-22 2021-10-08 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
CA3129404A1 (en) * 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated api particles produced by solventless mixing processes in aqueous suspension
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
CA2563409A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability
PL1799199T3 (pl) * 2004-10-08 2012-09-28 Novartis Ag Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca
US20100247645A1 (en) * 2007-09-28 2010-09-30 Catherine Curdy Pharmaceutical combination of aliskiren and valsartan

Also Published As

Publication number Publication date
IL213918A0 (en) 2011-07-31
BRPI1007452A2 (pt) 2016-02-16
AR075179A1 (es) 2011-03-16
CL2011001817A1 (es) 2012-01-13
CN102300558A (zh) 2011-12-28
PL2391345T3 (pl) 2015-03-31
KR20110117199A (ko) 2011-10-26
ECSP11011289A (es) 2011-09-30
RU2535090C2 (ru) 2014-12-10
MY153852A (en) 2015-03-31
AU2010209787B2 (en) 2013-06-06
MA33060B1 (fr) 2012-02-01
US20110287100A1 (en) 2011-11-24
ZA201104489B (en) 2012-02-29
TW201038300A (en) 2010-11-01
TWI468191B (zh) 2015-01-11
NZ593622A (en) 2013-12-20
EP2391345A1 (en) 2011-12-07
JP2012516299A (ja) 2012-07-19
TN2011000307A1 (en) 2012-12-17
MX2011007779A (es) 2011-08-12
WO2010086312A1 (en) 2010-08-05
AU2010209787A1 (en) 2011-07-14
ES2525648T3 (es) 2014-12-26
CA2749531A1 (en) 2010-08-05
SG172226A1 (en) 2011-07-28
PE20110943A1 (es) 2012-01-22
HK1161125A1 (en) 2012-08-24
RU2011135417A (ru) 2013-03-10
CO6400184A2 (es) 2012-03-15
EP2391345B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
ZA201106050B (en) Dye-polymers formulations
PL3061445T3 (pl) Silnie stężone preparaty farmaceutyczne
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
EP2504034A4 (en) TOPICAL IBUPROFEN FORMULATIONS
GB0815435D0 (en) Formulations
IL269369A (en) The vehicles are improved
GB2459691B (en) Formulations
IL218231A0 (en) Vesicular formulations
GB0823269D0 (en) Formulations
HK1161125A1 (en) Galenic formulations comprising aliskiren
GB0919210D0 (en) Formulations
GB0821789D0 (en) Formulations
ZA201106842B (en) Sanitizer formulations
EP2307021A4 (en) FORMULATIONS
IL217390A0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0917744D0 (en) Formulations
GB0914489D0 (en) Improved formulations
GB0918285D0 (en) Topical formulations
GB0918286D0 (en) Topical formulations
GB0807906D0 (en) Formulations
GB0811447D0 (en) Formulations
GB0816876D0 (en) Formulations